Hyperphosphatemia
-
Subject Areas on Research
- A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
- A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.
- Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications.
- Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies.
- Effects of phosphate binders in moderate CKD.
- Fibroblast growth factor 23 and the future of phosphorus management.
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
- Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey.
- Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
- Low socioeconomic status associates with higher serum phosphate irrespective of race.
- Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.
- Pharmacobezoar in a patient on an oral phosphate binder.
- Phosphate: a novel cardiovascular risk factor.
- Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.
- Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
- State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
- The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
- The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.